Researchers from Columbia University Report New Studies and Findings in the Area of Heart Failure (Reverse Remodeling Effects of Sacubitril-valsartan: Structural and Functional Optimization In Stage C Heart Failure).

A recent study conducted by researchers from Columbia University in New York City examined the effects of sacubitril-valsartan, a medication used to treat heart failure with reduced ejection fraction. The study involved 40 patients who were already receiving guideline-directed medical therapy for heart failure. The researchers found that after one year of treatment with sacubitril-valsartan, there was a significant decrease in left ventricular volume and an increase in left ventricular ejection fraction. Additionally, right ventricular volume decreased and right ventricular global longitudinal strain improved. These findings suggest that sacubitril-valsartan can induce significant remodeling of both the left and right ventricles in patients with heart failure. The study was supported by Novartis and has been peer-reviewed. [Extracted from the article]